His company SUPPLIES MDMA for 33 CLINICAL TRIALS worldwide

Nicholas Kadysh, CEO of PharmAla Biotech, shares insights into the practical aspects of providing MDMA for clinical research and the development of new drug analogs. PharmAla Biotech supports 33 clinical trials globally by supplying regulated MDMA, while also researching novel variants that potentially improve safety and therapeutic efficacy through a prosocial mechanism. The discussion challenges common misconceptions about MDMA and other controlled substances being inherently dangerous, highlighting instead their therapeutic potential when properly managed. The conversation also contrasts the regulatory environment in Canada with the model in Australia to illustrate how medical systems effectively oversee authorized prescribing, emphasizing that the therapeutic use of these substances requires safety and professional medical supervision.